Oragenics, Inc. (OGEN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oragenics, Inc. on January 8, 2018. The report discloses a corporate action regarding the Company's capital structure effective January 19, 2018.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate event rather than financial performance results.
Material Changes
- Reverse Stock Split: The Company announced a 1-for-10 reverse split of its common stock ($0.001 par value).
- Effective Date: The split is effective as of January 19, 2018.
- Trading Resumption: Common stock will begin trading on a split-adjusted basis on January 22, 2018, under the existing symbol "OGEN".
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard disclosure of the stock split mechanics. The primary purpose is to notify the market of the impending change in share count and price per share.
Investor Verification Checklist
- Confirm the 1-for-10 reverse split ratio and the January 19, 2018 effective date.
- Verify that trading will resume on January 22, 2018, under the symbol "OGEN".
- Review the attached Press Release (Exhibit 99.1) for details on fractional share handling and record dates.